We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Bristol Myers Squibb Co. closed 6.61% short of its 52-week high of $61.08, which the company reached on November 11th.

Hennion & Walsh Asset Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 33.8% during the ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company ( NYSE:BMY ), it is important to understand the ...